Skip to content
DataLookout
Menu

NCT01742299

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 42 versions: 31 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Oct 29, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Primary endpoints: 2 to 1
    • Secondary endpoints: 2 to 1
    • Study description expanded, about 54 words
    • Site details revised at 1 of 29 sites
  2. Notable Primary endpoints: 1 to 2
    • Secondary endpoints: 1 to 2
    • Site details revised at 1 of 29 sites
    v41
  3. Notable Enrollment target: 250 to 155v40
  4. Notable Enrollment target: 155 to 250v38 Show 4 more changesShow less
    • Eligibility criteria shortened, about 19 words
    • Primary endpoint revised
    • Secondary endpoint revised
    • Study description expanded, about 154 words
  5. Minor Trial completed
    • Primary and study completion dates changed from estimate of Apr 24, 2026 to Apr 20, 2026
    v37
  6. Notable Primary and study completion moved earlier from Apr 21, 2033 to Apr 24, 2026v34
  7. Minor Site details revised at 3 of 29 sitesv33
  8. Minor Site details revised at 1 of 29 sitesv32
  9. Minor Site details revised at 1 of 29 sitesv30
  10. Minor Study sites revised (29)v27
  11. Minor Study sites revised (29)v26
  12. Minor Study sites revised (29)v24
  13. Minor Study sites revised (29)v23
  14. Minor Study sites revised (29)v22
  15. Notable Primary and study completion dates: Apr 21, 2023 to Apr 21, 2033v18 Show 7 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Primary endpoint revised
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 250 to confirmed 155
    • Interventions: STI571 (Drug) to imatinib mesylate (Drug)
    • Secondary endpoint revised
    • Site details revised at 29 of 29 sites
  16. Minor Site details revised at 1 of 29 sitesv17
  17. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 155 to 250
    • Site details revised at 29 of 29 sites
    v16
  18. Minor Site details revised at 1 of 29 sitesv14
  19. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 250 to confirmed 155
    • Study sites: 28 to 29
    v13
  20. Minor Study sites revised (28)v12
  21. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 152 to 250
    • Primary and study completion dates: Jun 21, 2024 to Apr 21, 2023
    • Study sites revised (28)
    v11
  22. Minor Site details revised at 1 of 28 sitesv10
  23. Minor Primary and study completion dates: Jun 2024 to Jun 21, 2024
    • Start date: Mar 2013 to Mar 26, 2013
    • Site details revised at 4 of 28 sites
    v9
  24. Minor Primary and study completion dates: Oct 2024 to Jun 2024v8
  25. Notable Primary and study completion dates: Sep 2023 to Oct 2024
    • Enrollment target: 150 to 152
    • Study sites: 27 to 28
    v7
  26. Notable Primary and study completion dates: Mar 2022 to Sep 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 250 to confirmed 150
    • Study sites: 33 to 27
    v6
  27. Notable Primary and study completion dates: Feb 2015 to Mar 2022
    • Study sites revised (33)
    v5
  28. Notable Primary and study completion dates: Aug 2018 to Feb 2015
    • Study sites: 31 to 33
    v4
  29. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 24 to 31
    • Primary and study completion dates: Feb 2018 to Aug 2018
    v3
  30. Notable Primary and study completion dates pushed to Feb 2018
    • Study sites: 4 to 24
    • Start date: Feb 2013 to Mar 2013
    v2
  31. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Frequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)

Secondary (1)

Proportion of Participants With Clinical Benefit as Assessed by the Investigator

Arms and interventions

imatinib mesylateExperimental

Patients who completed a previous Novartis-sponsored imatinib study, continued to derive clinical benefit from treatment, and entered this roll-over study to receive ongoing imatinib therapy. Treatment continued until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, non-compliance, investigator decision, death, or transition to commercial supply, as applicable.

Drugs: imatinib mesylate

Sites

29 sites in 11 countries

United States 9, China 5, France 3, Singapore 3, Romania 2, United Kingdom 2, Finland 1, Hong Kong 1, Switzerland 1, Thailand 1, Turkey (Türkiye) 1